Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
about
Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea.Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.pS2 is an independent factor of good prognosis in primary breast cancer.Expression of transforming growth factor beta mRNA isoforms in human breast cancerDoes the oestrogen receptor concentration of a breast cancer change during systemic therapy?Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.Primary systemic therapy for operable breast cancerOestrogen receptor: a stable phenotype in breast cancerChanges in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapyPS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancerPrimary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update.Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancerOutcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.The differing predictive values of oestrogen receptor assays for large breast cancers.Letrozole as primary medical therapy for locally advanced and large operable breast cancer.Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.
P2860
Q34087879-2F7916B3-7475-4826-AD67-B2AE2D9C06ACQ35805644-9AF02028-5DC8-4AB9-9131-7122640249A0Q35976164-33A27BFE-6BD0-4060-9EE4-DFF397FD0A20Q35979175-26F1D4BF-F424-4D52-9FF7-BE9B9C404B22Q35982673-2A9B3F43-A5D5-4CB4-8ED5-CFFE4B4CCBC1Q35984169-6CB24110-6307-4EB0-A359-F1D7A6A73155Q35984252-AB2976AC-A942-44E8-9F93-45381F06BA2AQ36134377-19F0C217-0120-4578-BF8C-2C5C51CAA312Q36135815-8F19FCB1-11F8-40B7-A21F-8CBC8354DB37Q36295086-5C1CF5CC-E517-42AF-8355-7ADD61EAC055Q36431261-DFB3253F-AEC1-4E00-8E4B-FA9F5DB1410BQ36470650-BD953F51-68FC-4543-8931-D40CE14169FFQ36624026-5B3AA4B4-36FE-4F1A-BDB1-8810B8353BE6Q36624255-839CE061-E21C-4E5C-90AB-CECABF4BF1C1Q36682964-30CE490C-1416-42A2-8F5D-5181774EA7BEQ43711061-A07BFEFD-DCD8-4DDA-AD91-89865306B77EQ55093318-F8F315F4-EC15-438D-930C-A519D0499C1C
P2860
Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Response to endocrine manipula ...... perable primary breast cancer.
@ast
Response to endocrine manipula ...... perable primary breast cancer.
@en
type
label
Response to endocrine manipula ...... perable primary breast cancer.
@ast
Response to endocrine manipula ...... perable primary breast cancer.
@en
prefLabel
Response to endocrine manipula ...... perable primary breast cancer.
@ast
Response to endocrine manipula ...... perable primary breast cancer.
@en
P2093
P2860
P356
P1476
Response to endocrine manipula ...... perable primary breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1989.256
P407
P577
1989-08-01T00:00:00Z